title: Reduced neutrophil CD10 expression in nonhuman primates and humans after in vivo challenge with E. coli or lipopolysaccharide.
abstract: CD10, also known as neutral endopeptidase or CALLA, is a major metalloproteinase that regulates levels of biologically active peptides that initiate inflammatory, cardiovascular, and neurogenic responses. Relative tissue expression levels of CD10, its peptide substrates, and their receptors constitute the basic regulatory mechanism. Neutrophils contain abundant CD10 and are rapid responders to an inflammatory septic challenge. Expression of neutrophil surface antigens in response to inflammation was studied in the primate model of Escherichia coli-mediated sepsis and in human volunteers injected with lipopolysaccharide (LPS). There was a rapid and profound (up to 95%) reduced baboon neutrophil CD10 expression in response to E. coli injections of 5.71 x 106 CFU/kg to 2.45 x 109 CFU/kg that gradually resolved to preinjection levels. The reduction was both dose and time dependent. Reduced CD10 antigen on mature baboon neutrophils and bands was observed by immunohistochemistry. Human volunteers challenged with 4ng/kg LPS experienced transient chills, nausea, fever, and myalgia. Up to approximately 20% of their neutrophils had reduced CD10 expression, peaking at 2 to 8 h after injection. By 24 h, neutrophil CD10 expression resolved to preinjection levels. In contrast, in both the baboon and human studies, other neutrophil surface antigens were only slightly decreased (CD11a) or increased (CD11b, CD18, CD35, CD66b, and CD63). These data present the novel observation that neutrophil CD10 expression decreases significantly in response to in vivo inflammatory challenge. This decrease appears to be unique to CD10 and may contribute to a reduced regulation of bioactive peptides released in response to inflammatory challenge.
authors.affiliation: Free Radical Biology and Aging Research, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kaneko
authors.forename: D J
authors.initials: DJ
authors.lastname: Stearns-Kurosawa
authors.forename: Fletcher
authors.initials: F
authors.lastname: Taylor
authors.forename: Michaele
authors.initials: M
authors.lastname: Twigg
authors.forename: Koichi
authors.initials: K
authors.lastname: Osaki
authors.forename: Gary T
authors.initials: GT
authors.lastname: Kinasewitz
authors.forename: Glenn
authors.initials: G
authors.lastname: Peer
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Kurosawa
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000378:metabolism*; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation; D008070:Lipopolysaccharides / Q000378:metabolism*; D015260:Neprilysin / Q000096:biosynthesis* / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism*; D010215:Papio; D018805:Sepsis / Q000276:immunology; D013234:Stem Cells; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D008070:Lipopolysaccharides; D015260:Neprilysin